Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASH 2014 /
Compound improves survival in aggressive acute myeloid leukaemia with manageable added toxicity in phase III trial

6th - 9th Dec 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.12.14
Views: 1723
Rating:

Dr Farhad Ravandi - MD Anderson Cancer Center, Houston, USA

At a press conference at ASH 2014, Dr Ravandi presents the findings of a phase III randomised trial which looked at combining cytarabine with new agents in order to develop an effective treatment for acute myeloid leukaemia (AML) that does not cause the current levels of toxicity associated with it.

Read the news story and watch the interview for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation